First of all, there is need to set forth the facts that must be incorporated into and explained by an operational model.
1) 25(OH)D, whether given as such, or produced through cholecalciferol administration, unquestionably increases calcium absorption efficiency under certain conditions. This has been established with different interventional designs by a variety of investigative groups for at least the last 35 y (2-7) and has been shown to be true even in anephric patients (5) . But this is not to propose that 25(OH)D is in any sense a ''regulator'' of calcium absorption as Nordin (8) To explain this seeming paradox, as some have attempted to do, by proposing that the intestinal requirement for calcitriol is higher than normal in vitamin D deficiency is to beg the question, What is it that these individuals are lacking? The most obvious answer to that question is not calcitriol but 25(OH)D. And, in fact, supplying that molecule normalizes absorption.
I cannot definitively say why Aloia et al (1) failed to find an effect of 25(OH)D in their observational study; nor can I say why it is that the absorptive apparatus appears to need both molecules. Nevertheless taking this dual need as fact, it is possible to propose a satisfactory model that integrates all 4 of the above points. In this model, 25(OH)D does not elevate calcium absorption in its own right but is permissive rather than directly causal. The actual regulatory stimulus for absorption is precisely calcitriol, as I believe we all agree. Renal production of calcitriol is regulated in the usual way mainly by parathyroid hormone. But actual mucosal response to calcitriol is Can one characterize those individuals whose calcium absorption improves with a rise in 25(OH)D? I suggest that they are individuals with vitamin D status at the low end of the continuum who have a mild degree of calcium hunger, ie, whose systems are attempting to retain calcium. For whatever reason (low net intake, excessive loss, net bone accretion), they are unable to meet fully the endogenous need for calcium. An example would be the bisphosphonate-treated patients in the report by Kendler et al (6) , a situation known to lower serum calcium and elevate parathyroid hormone. Conversely, those who show no response despite comparably low concentrations of 25(OH)D are those with efficient renal control of calciuria, those with high calcium intakes, or those with primary bone loss (as in the perimenopause).
Mechanistically, it would be highly desirable to understand the molecular basis for the demonstrable effect of 25(OH)D under these circumstances. Nevertheless, lacking that understanding, it is necessary to recognize the fact of the 25(OH)D effect. In the practical order, that means ensuring a 25(OH)D concentration of at least 30 ng/mL.
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